ClinicalTrials.gg
CompletedNCT05472324Updated Nov 20, 2025

Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.

A Phase 2 interventional study of TQC2731 injection and Placebo in Severe Asthma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Enrollment
91st of 182
205 · median 203
Started
2022
with 20 others
Phase 2
39 of 251
19 open now
Registered
122nd of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 91st largest by enrollment of the 182 interventional ones that give a count, is one of 21 that started in 2022, is one of 39 in phase 2, and was the 122nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This is a phase II, multicenter, double-blind, randomized, parallel group, placebo-controlled clinical study to evaluate the effect of three doses of TQC2731 on Annualized Asthma Exacerbation Rates(AAER) in adult subjects with poor control of severe asthma. It is estimated that 220 subjects will be included. The subjects will receive TQC2731 (70 mg Q4w, 210 mg Q4w, 420 mg Q4w) or placebo (Q4w) administered by Subcutaneous (SC) in the ratio of 1:1:1:1.

The study comprised a 5 to 6-week screening period, a 52-week treatment period and a 12-week follow-up period. During the treatment period, the study drug will be administered from day 0 until week 48. The study drug was not administered at the 52nd week.

03

Conditions studied

  • Severe Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 Age. 18-75
  • 2 Documented physician-diagnosed asthma for at least 12 months before visit 1.
  • 3 Subjects who have received a physician-prescribed asthma controller medication with medium or high dose inhaled glucocorticosteroid (ICS) for at least 12 months before visit 1.
  • 4 Documented treatment with a total daily dose of either medium or high dose ICS for at least 3 months before visit 1.
  • 5 At least one additional maintenance asthma controller medication such as Long acting β2 receptor agonist (LABA), leukotriene receptor antagonist (LTRA), theophylline, Long-acting muscarinic antagonists (LAMA), sodium cromoglycate, etc. is required according to standard practice of care and must be documented for at least 3 months.
  • 6 Morning pre-BD \<80% predicted normal At visit 2 or visit 2a.
  • 7 Evidence of asthma as documented by either: Documented historical reversibility of FEV1 ≥12% and ≥200 mL in the previous 12 months before visit 1 OR Post-BD (albuterol/salbutamol) reversibility of FEV1 ≥12% and ≥200 mL during screening At visit 2 or visit 2a.
  • 8 Documented history of at least 2 asthma exacerbation events within 12 months before visit 1.
  • 9 ACQ-6 score ≥1.5 at visit 1
  • 10 Body weight ≥ 40 kg at visit 1.

Exclusion criteria

Exclusion Criteria:

  • 1 Pulmonary disease other than asthma.
  • 2 History of cancer.
  • 3 Current smokers or subjects with smoking history ≥10 pack-years.
  • 4 , C, (HIV) or Syphilis.
  • 5 History of anaphylaxis following any biologic therapy.
  • 6 History of chronic alcohol or drug abuse within 12 months.
  • 7 History of a infection.
  • 8 Pregnant or breastfeeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
205 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo, subcutaneous administration, 4 weeks as a treatment cycle.

    Drug: Placebo

  • Experimental
    TQC2731 injection 70 mg

    TQC2731 injection 70 mg, subcutaneous administration, 4 weeks as a treatment cycle.

    Drug: TQC2731 injection

  • Experimental
    TQC2731 injection 210 mg

    TQC2731 injection 210 mg, subcutaneous administration, 4 weeks as a treatment cycle.

    Drug: TQC2731 injection

  • Experimental
    TQC2731 injection 420 mg

    TQC2731 injection 420 mg, subcutaneous administration, 4 weeks as a treatment cycle.

    Drug: TQC2731 injection

Interventions

  • TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.

  • DrugPlacebo

    The drug is a placebo Comparator.

06

What researchers measure

Primary outcomes

  1. Annual Asthma Exacerbation Rate

    The annual exacerbation rate is based on annualized asthma exacerbation rates reported by the investigator in the electronic case report form(eCRF). The analysis is based on the primary population (Full Analysis Set)

    Time frame: Baseline up to Study Week 64

Secondary outcomes

  1. Change from baseline in forced expiratory volume in first second(FEV1) of Pre-dose and Pre-bronchodilator (Pre-BD).

    FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

    Time frame: Baseline up to Study Week 64

  2. Mean Change From Baseline in Weekly Rescue Medication Use

    Daily rescue medication use is defined as: Number of night inhaler puffs + 2 x \[number of night nebulizer times\] + number of daytime inhaler puffs + 2 x \[number of day nebulizer times\]. Weekly means are calculated using at least 4 of 7 days of daily rescue medication use.

    Time frame: Baseline up to Study Week 64

  3. Change From Baseline in Clinic Fractional Exhaled Nitric Oxide (FeNO) (Ppb) .

    Mean change from baseline in FeNO (Ppb)

    Time frame: Baseline up to Study Week 64

  4. Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ(S)+12) Total Score

    The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).

    Time frame: Baseline up to Study Week 64

  5. Change From Baseline in Asthma Control Questionnaire-6(ACQ-6)

    The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.

    Time frame: Baseline up to Study Week 64

  6. Mean Change From Baseline in Asthma Symptom Diary

    Mean change from baseline at Week 52 in Asthma Symptom Diary (ASD). The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4, where 0 indicates no asthma symptoms.

    Time frame: Baseline up to Study Week 52

  7. Change From Baseline in 5-level EuroQol 5-dimensional questionnaire (EQ-5D-5L) VAS

    Mean change from baseline in EQ-5D-5L VAS. EQ-5D-5L visual analogue scale (VAS) allows subjects to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state. EQ-5D-5L VAS.

    Time frame: Baseline up to Study Week 64

  8. Time to First Asthma Exacerbation

    Time to first occurrence of asthma exacerbation post-randomisation, presented as number of subjects with at least one asthma exacerbation as reported by the investigator in the eCRF.

    Time frame: Baseline up to Study Week 64

  9. Proportion of subjects with at least one asthma exacerbation

    Proportion of subjects with at least one asthma exacerbation as recorded by the investigator in the Case Report Form(CRF). This is presented as proportion of subjects with at least one asthma exacerbation.

    Time frame: Baseline up to Study Week 64

  10. Incidence and severity of adverse events (AE)

    The incidence of adverse events in subjects recorded by the investigator in CRF. The evaluation criteria for the severity of adverse events were carried out in accordance with \[NCI- CTCv5.0\].

    Time frame: Baseline up to Study Week 64

  11. Mean Change From Baseline in Morning and Evening Peak Expiratory Flow (PEF) (Weekly Means).

    Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.

    Time frame: Baseline up to Study Week 64

  12. Mean Change From Baseline in Night Time Awakenings (Weekly Means)

    Night-time awakenings percentage defined as number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data and multiplied by 100%. At least 4 out of 7 days of data is required to calculate a weekly mean.

    Time frame: Baseline up to Study Week 64

  13. Change From Baseline in Blood Eosinophils .

    Mean change from baseline in Blood Eosinophils measured at site

    Time frame: Baseline up to Study Week 64

  14. Change From Baseline in Total Serum immunoglobulin E(IgE).

    Mean change from baseline in Total Serum IgE measured at site

    Time frame: Baseline up to Study Week 64

  15. Incidence and severity of serious adverse events (SAE)

    The incidence of serious adverse events in subjects recorded by the investigator in CRF. The evaluation criteria for the severity of serious adverse events were carried out in accordance with \[NCI-CTCv5.0\].

    Time frame: Baseline up to Study Week 64

  16. abnormal laboratory test indicators

    Researchers make medical judgment according to the severity of abnormal indicators and the relevant conditions of patients' diseases.

    Time frame: Baseline up to Study Week 64

07

Study locations

2 sites
  • GUANGZHOU FIRST PEOPLE's HOSPITAL
    Guangzhou, Guangdong 510180, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Mar 2025, 29 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 29 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2022
First posted
Jul 25, 2022
StartActual
Sep 23, 2022
Primary completionActual
Mar 5, 2025
CompletionActual
Mar 5, 2025
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05472324
Responsible party
Sponsor
First posted
Jul 25, 2022
Start date
Sep 23, 2022
Primary completion
Mar 5, 2025
Completion
Mar 5, 2025
Last update
Nov 20, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC2731

Start the discussion